Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Source: NASDAQ.COM
- Revenue Growth: Amicus Therapeutics reported a 24% year-over-year increase in net product revenue for Q4, reaching $185.21 million, primarily driven by sales of Galafold and Pombiliti + Opfolda, indicating sustained market demand in the rare disease treatment sector.
- Net Income Fluctuation: Despite adjusted net income rising from $29.19 million to $31.63 million, equating to $0.10 per share, the company's net income plummeted to $1.69 million, reflecting the pressure on profitability from increased share-based compensation expenses.
- Annual Performance Improvement: For the full year 2025, adjusted net income increased to $96.76 million or $0.31 per share, demonstrating effective strategies in product sales and cost control, although net loss narrowed to $27.11 million.
- Acquisition Agreement: In December 2025, Amicus entered into a definitive agreement to be acquired by BioMarin Therapeutics for $14.50 per share, totaling approximately $4.8 billion, with the transaction expected to close in Q2 2026, marking a significant strategic shift for the company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
